IQ-AI Limited (LON:IQAI) subsidiary Imaging Biometrics’ said its brain tumour imaging platform has been by purchased by the Los Angeles County Hospital.
Samarkand Group PLC (LON:SMK) said it has formally opened its new office in Tokyo to serve the Japanese market.
ANGLE PLC (LON:AGL) confirmed that it has completed the work required to answer questions raised by the US Food and Drugs Administration (FDA) in its Additional Information Request and that a comprehensive response has been submitted as planned.
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) said had finished recruitment of the first part of its phase I/II evaluation of MRx-4DP0004 in patients with partly controlled asthma.
Polarean Imaging PLC (LON:POLX) is looking forward to furthering the global understanding of the COVID-19 medical case, it said in its 2020 results statement. The medical imaging technology company said its technology will provide the types of quantitative information necessary for fully understanding COVID-19’s mechanisms and post-infection consequences.
Supply@ME PLC (LON:SYME) said it will now publish its 2020 accounts following completion of the funding facility with a group of new investors, which it said will support its strategic developments. As a result, the firm said its 2020 AGM is also being rescheduled in order to give shareholders the requisite notice of meeting.
Redx Pharma PLC (LON:REDX) said it has appointed Ernst & Young LLP (EY) as the company’s auditor for the financial year ending September 30, 2021.
Bloomsbury Publishing PLC (LON:BMY) said chief executive Nigel Newton and group finance director Penny Scott-Bayfield will provide a live presentation relating to its results for the year ended February 28, 2021 via the Investor Meet Company platform on June 14, 2021 at 10am BST.
TomCo Energy PLC (LON: TOM) said Robert Kirchner had resigned as a non-executive director with immediate effect. Tomco will be able to receive Kirchner’s advice for the next 12 months through a £32,500 departure arrangement.
Arix Bioscience PLC (LON:ARIX) said its portfolio company, Harpoon Therapeutics today presented interim data from the ongoing dose-escalation portion of a Phase 1/2a trial for its lead programme, HPN424, in patients with metastatic castration-resistant prostate cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.